Results 141 to 150 of about 67,803 (296)
Lower Satisfaction and Inferior Outcomes Associated With Delayed Surgery for Chronic Quadriceps Tendon Ruptures: A Systematic Review
Arthroscopy, Sports Medicine, and Rehabilitation, EarlyView.Purpose
To evaluate the literature regarding the efficacy of various repair and reconstruction surgical techniques for chronic quadriceps tendon ruptures (QTRs) in native knees and to assess their associated outcomes. Methods
A comprehensive literature search of the EMBASE, PubMed/MEDLINE, and Cochrane databases was conducted from October 2023 to ...Matthew R. Bryan, Michael Mazzucco, Arsen Omurzakov, Alex E. White, Prashanth Kumar, Tyler Uppstrom, Nicolas Pascual‐Leone, Stephen O’Brien, Samuel A. Taylor +8 morewiley +1 more sourceLoss of Reduction and Clavicle Fractures Commonly Occur in Patients Undergoing Acromioclavicular Joint Reconstruction and Female Sex Is Associated With Higher Fracture Risk
Arthroscopy, Sports Medicine, and Rehabilitation, EarlyView.Purpose
To use a large, multi‐institutional database to characterize the outcomes and complication profile after primary acromioclavicular (AC) joint reconstruction and to evaluate potential sex‐related differences in outcomes and complications. Methods
The TriNetX national database was queried for patients undergoing AC joint reconstruction between ...Scott Fong, Arthur Saroyan, Rajiv S. Vasudevan, Michael S. Lee, Louise A. Atadja, Peter F. Monahan, Jay Moran, Kevin Girardi, Jacob D. Kodra, Jonathan Salandra, Andrew E. Jimenez +10 morewiley +1 more sourceEfficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study
Arthritis &Rheumatology, EarlyView.Objective
To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb +12 morewiley +1 more sourceComparative studies of RNFL thickness measured by OCT with global index of visual fields in patients with ocular hypertension and early open angle glaucoma
Clinical Ophthalmology, 2009 Sergios Taliantzis, Dimitris Papaconstantinou, Chrysanthi Koutsandrea, Michalis Moschos, Michalis Apostolopoulos, Gerasimos GeorgopoulosAthens University Medical School, Department of Ophthalmology, Athens, GreecePurpose: To compare the functional ...Sergios Taliantzis, Dimitris Papaconstantinou, Chrysanthi Koutsandrea, Michalis Moschos, et al. +4 moredoaj Unveiling Endotypes in Systemic Lupus Erythematosus Through Multiomic Analysis: Insights Into Cardiovascular and Renal Complications
Arthritis &Rheumatology, EarlyView.Objective
Systemic lupus erythematosus (SLE) shows clinical and molecular heterogeneity, and cardiovascular (CV) complications and lupus nephritis (LN) remain leading causes of morbidity and mortality. This study investigated whether omic profiling can reveal molecular endotypes linked to these outcomes.Tomás Cerdó, Laurel Woodridge, Sagrario Corrales, Juan Rafael Muñoz‐Castañeda, Ana Isabel Torralbo, Anisur Rahman, Filipa Farinha, Rafaela Ortega Castro, Pedro Segui, Ismael Sanchez‐Pareja, Laura Muñoz‐Barrera, Christian Merlo, Desiree Ruiz‐Vilchez, M. Carmen Ábalos‐Aguilera, Pilar Font, Nuria Barbarroja Puerto, PRECISESADS Clinical Consortium, Lorenzo Beretta, Barbara Vigone, Jacques‐Olivier Pers, Alain Saraux, Valérie Devauchelle‐Pensec, Divi Cornec, Sandrine Jousse‐Joulin, Bernard Lauwerys, Julie Ducreux, Anne‐Lise Maudoux, Carlos Vasconcelos, Ana Tavares, Esmeralda Neves, Raquel Faria, Mariana Brandão, Ana Campar, António Marinho, Fátima Farinha, Isabel Almeida, Miguel Angel Gonzalez‐Gay Mantecón, Ricardo Blanco Alonso, Alfonso Corrales Martínez, Ricard Cervera, Ignasi Rodríguez‐Pintó, Gerard Espinosa, Rik Lories, Ellen De Langhe, Nicolas Hunzelmann, Doreen Belz, Torsten Witte, Niklas Baerlecken, Georg Stummvoll, Michael Zauner, Michaela Lehner, Eduardo Collantes, Ma Carmen Castro‐Villegas, Norberto Ortego, María Concepción Fernández Roldán, Enrique Raya, Inmaculada Jiménez Moleón, Enrique de Ramon, Isabel Díaz Quintero, Pier Luigi Meroni, Maria Gerosa, Tommaso Schioppo, Carolina Artusi, Carlo Chizzolini, Aleksandra Zuber, Donatienne Wynar, Laszló Kovács, Attila Balog, Magdolna Deák, Márta Bocskai, Sonja Dulic, Gabriella Kádár, Falk Hiepe, Velia Gerl, Silvia Thiel, Manuel Rodriguez Maresca, Antonio López‐Berrio, Rocío Aguilar‐Quesada, Héctor Navarro‐Linares, Marta Alarcón‐Riquelme, Alejandro Escudero‐Contreras, M. Ángeles Aguirre‐Zamorano, Carlos Perez‐Sanchez, Elizabeth C. Jury, Chary Lopez‐Pedrera +84 morewiley +1 more sourceIxekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial
Arthritis &Rheumatology, EarlyView.Objective
Overweight or obesity is prevalent in 72% to 82% of individuals with psoriatic arthritis (PsA). We assessed the efficacy and safety of ixekizumab (IXE) concomitantly administered with tirzepatide (TZP) compared with IXE alone in adult participants with active PsA and overweight with at least one weight‐related comorbidity or obesity.Joseph F. Merola, Philip Mease, Alan Kivitz, Naveed Sattar, Laura C. Coates, Daniel Aletaha, Cynthia E. Kartman, Peter Fischer, Luna Sun, Píndaro Martínez‐Osuna, Andris Kronbergs, Purvi Prajapati, Anabela Cardoso, Mark C. Genovese, Alexis Ogdie +14 morewiley +1 more sourceMachine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration
Arthritis &Rheumatology, EarlyView.Objective
To develop, externally validate, and simplify a machine learning model to predict remission between 6 and 24 months in patients with rheumatoid arthritis (RA) initiating tumor necrosis factor inhibitors, JAK inhibitors, interleukin‐6 inhibitors, abatacept, or rituximab using data from 11 international registries in the JAK‐pot collaboration ...Zubeyir Salis, Denis Mongin, Denis Choquette, Louis Coupal, Catalin Codreanu, Florenzo Iannone, Roberto Caporali, Tore K. Kvien, Sella Provan, Ruth Fritsch‐Stork, Dan Nordström, Nina Trokovic, Karel Pavelka, Jakub Závada, Ana Rodrigues, Ziga Rotar, Prodromos Sidiropoulos, Irini Flouri, Céline Lamacchia, Michele Iudici, Delphine Courvoisier, Kim Lauper, Axel Finckh +22 morewiley +1 more source